webinars
In drug development, there is a growing demand for ultrasensitive bioanalytical platforms and kits, especially in disciplines like neuroscience, where analytes are often present at very low concentrations in peripheral circulation. KCAS Bio addresses this demand by offering a spectrum of technologies, from dedicated platforms to ultra-sensitive kits on conventional…
Blogs
What is immunogenicity? Immunogenicity refers to the ability of a substance, such as a New Biological Entity (NBE) or a vaccine, to provoke an immune response when administered in the body. The recognition of the substance as foreign triggers an immune response, which involves the production of antibodies and the…
Blogs
What Are Neutralizing Antibody (NAb) Assays? Neutralizing antibodies (NAbs) are a subset of anti-drug antibodies (ADAs) that play an important role in evaluating the immunogenicity, safety, and efficacy of a drug product. While most drugs carry a low risk of eliciting NAbs and do not require a validated NAb…
Blogs
Why Immunogenicity in Drug Development Matters Immunogenicity, why do we keep talking about it? Immunogenicity can, in the simplest of terms, be described as a subject’s ability to generate antibodies specific to the dosed protein therapeutic. Immunogenicity can be either a wanted or unwanted reaction. Wanted immunogenicity is the desired…
November 5
- November 9
KCAS Bio will be participating in Society for Immunotherapy of Cancer (SITC) 2025, taking place on November 5-9 in National Harbor, MD. SITC 2025 convenes researchers, clinicians, and biopharmaceutical developers to explore the latest breakthroughs in immune-based cancer treatments. These field experts will discuss cutting-edge research and clinical needs within…
October 7
- October 10
KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused tracks on…
Podcasts
In Episode 88 of The Weekly Bioanalysis, hosts Dominic Warrino, Ph.D. and John Perkins, Ph.D present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. David Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across…
Blogs
Initially developed to assess the frequency of circulating antigen-specific Antibody-Secreting Cells (ASC), ELISpot has become a vital tool for quantifying antigen-reactive T-cells by measuring secreted immune mediators such as cytokines or key molecules involved in cell-mediated cytotoxicity. Compared to other assays for monitoring cell-mediated immunity (CMI), such as…
Podcasts
In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their…
webinars
As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.
Blogs
Last month, Elodie, Magali, and I found ourselves in Lisbon—not for a spring getaway (though the weather was a delightful preview of the season) and certainly not for ultra-trail training (although the city’s hills did give our calves a solid workout!). Instead, we were there for EIP, an event…
Podcasts
During episode 86 of KCAS Bio’s “The Weekly Bioanalysis” podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard…